Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 1(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04166474Phase 4Completed

Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin

Role: lead

NCT01784302Phase 1Completed

The Effect of Antacids and Multivitamins on Raltegravir

Role: lead

NCT01424826Phase 1Completed

The Effect of Intermittent Rifampicin on Raltegravir

Role: lead

All 3 trials loaded